Hemochromatosis

Hereditary hemochromatosis (HH) is the most common autosomal recessive genetic disorder in people of Northern European descent, causing the body to absorb two to three times more iron from food than it actually needs. Over decades, this excess iron deposits in vital organs — the liver, heart, pancreas, and joints — silently causing damage long before symptoms appear. Because treatment is simple, inexpensive, and highly effective when started early, recognizing hemochromatosis before organ damage occurs can mean a completely normal lifespan. The classic triad of "bronze diabetes" — bronze skin pigmentation, liver disease, and diabetes — represents late-stage disease that modern diagnosis aims to prevent.

Table of Contents

  1. Overview and History
  2. Genetics and Molecular Mechanism
  3. Pathophysiology: Iron Deposition by Organ
  4. Clinical Manifestations
  5. Diagnosis
  6. Treatment: Phlebotomy and Beyond
  7. Screening and Prevention
  8. Prognosis and Complications
  9. Key Research Papers
  10. References
  11. Connections

Overview and History

Hemochromatosis was first described in 1865 by French physician Armand Trousseau, who noted the association between cirrhosis, bronze skin, and diabetes — a triad he called "bronze diabetes" (diabète bronzé). The German pathologist Friedrich Daniel von Recklinghausen coined the term hemochromatosis in 1889, recognizing that iron accumulation was the common thread.

For over a century, the disease was considered rare and invariably fatal. That view changed dramatically in 1996 when Feder and colleagues at Mercator Genetics identified the HFE gene and its key mutations — C282Y and H63D — making population-level genetic testing possible. We now know hereditary hemochromatosis is one of the most common inherited disorders in people of Northern European ancestry, affecting approximately 1 in 200 to 1 in 400 individuals as C282Y homozygotes.

Despite this high prevalence, most people who carry two copies of the C282Y mutation never develop severe organ disease — a puzzle that researchers attribute to differences in dietary iron intake, alcohol use, other modifier genes, and the protective effect of menstruation in women. Clinical disease is five to ten times more common in men than in women; menstrual blood loss removes iron continuously and delays significant organ loading by one to two decades.

Today hemochromatosis is classified into four types based on genetic cause: Type 1 (HFE-related, by far the most common in Western populations), Type 2 (juvenile hemochromatosis, HJV or HAMP mutations, presents in the second or third decade), Type 3 (TFR2 mutations), and Type 4 (SLC40A1/ferroportin mutations, autosomal dominant). This article focuses on Type 1 HFE-related hemochromatosis.

Genetics and Molecular Mechanism

The HFE gene sits on chromosome 6p21.3, near the major histocompatibility complex. It encodes a 343-amino-acid transmembrane protein structurally similar to MHC class I molecules. Two missense mutations account for nearly all clinical disease:

Normally, HFE protein on intestinal crypt cells and hepatocytes interacts with transferrin receptors to sense circulating iron levels. When iron is adequate, HFE signaling — via BMP-SMAD and JAK-STAT pathways — stimulates the liver to produce hepcidin, the master iron regulatory hormone. Hepcidin is a small peptide secreted by hepatocytes that binds to ferroportin, the only known cellular iron exporter, triggering its internalization and degradation.

In HFE hemochromatosis, this sensing mechanism fails. Mutant HFE protein cannot properly transduce the "iron is sufficient" signal, so hepcidin production remains inappropriately low even when body iron stores are elevated. With ferroportin unchecked, duodenal enterocytes export dietary iron into the bloodstream at nearly twice the normal rate — roughly 3–4 mg per day instead of the normal 1–2 mg. Since the body has no active mechanism to excrete excess iron, it accumulates at approximately 0.5–1.0 g per year, eventually reaching total loads of 20–40 g (compared to a normal body iron store of 3–5 g).

This slow accumulation explains why symptoms typically emerge in men in their 40s and 50s — by which time decades of quiet iron loading have overwhelmed the liver's storage capacity and begun depositing iron in parenchymal cells elsewhere.

Pathophysiology: Iron Deposition by Organ

Iron toxicity operates primarily through the Fenton reaction: free iron catalyzes the conversion of hydrogen peroxide into highly reactive hydroxyl radicals, causing lipid peroxidation, protein oxidation, and DNA strand breaks. The pattern of organ involvement follows the distribution of transferrin-receptor-independent iron uptake.

Liver

Iron deposition begins in periportal hepatocytes (zone 1) and gradually spreads to mid-lobular and then centrilobular cells. Kupffer cells and bile duct epithelium are relatively spared early on. Hepatocyte iron triggers oxidative stress, activating stellate cells and promoting collagen deposition. The progression is: steatosis → fibrosis → cirrhosis → hepatocellular carcinoma. Cirrhosis typically requires 20+ years of untreated iron loading. Once cirrhosis is established, the risk of hepatocellular carcinoma (HCC) is increased 20-fold, and this risk persists even after successful iron depletion.

Pancreas

Iron deposits preferentially in the exocrine acinar cells first, later in the endocrine islet cells. Selective destruction of beta cells impairs insulin secretion, producing diabetes mellitus — "bronze diabetes" in the classic triad. The pancreatic damage is often irreversible even after iron depletion, so diabetes may persist despite successful phlebotomy treatment.

Heart

Cardiac iron accumulates in cardiomyocytes, leading initially to diastolic dysfunction (stiff, poorly filling ventricles), then progressing to dilated or restrictive cardiomyopathy. Arrhythmias — supraventricular tachycardias, heart block — can occur. Cardiac complications are the leading cause of death in juvenile hemochromatosis (Type 2), where iron loading is more rapid. In adult-onset HFE hemochromatosis, cardiac disease is usually a late manifestation but is one of the more reversible complications with early phlebotomy treatment.

Skin

The characteristic bronze or slate-gray skin pigmentation results from two mechanisms: direct iron deposition in dermal macrophages and the stimulation of melanin production by iron-laden skin cells. Sun-exposed areas are most prominently affected. Skin bronzing typically appears after significant iron loading and is a late clinical sign.

Pituitary and Gonads

Iron deposits in the anterior pituitary suppress production of LH and FSH, resulting in secondary hypogonadism. In men this causes reduced libido, impotence, testicular atrophy, and loss of body hair. In women it causes amenorrhea. Because gonadotropin deficiency usually predates testicular or ovarian failure, these symptoms may partially reverse with successful treatment if the pituitary is not too severely damaged.

Joints

Iron deposits in synovial tissue cause chronic inflammatory arthropathy. The classic pattern is involvement of the 2nd and 3rd metacarpophalangeal (MCP) joints — the "iron fist" sign. A firm, bony swelling of these knuckles, often with chondrocalcinosis visible on X-ray (calcium pyrophosphate crystal deposition), is a helpful clinical clue. Joint disease is one of the least responsive manifestations to phlebotomy treatment and often progresses even after iron depletion.

Clinical Manifestations

Hemochromatosis is famously insidious. Most patients accumulate significant iron for 20–40 years before symptoms appear, and early symptoms are non-specific. The three most common initial complaints are fatigue, joint pain, and abdominal pain — none of which point uniquely to iron overload. Many diagnoses are now made incidentally when routine blood tests reveal elevated transferrin saturation or ferritin.

Early Symptoms

The Classic Triad (Late Disease)

The "bronze diabetes" triad — cirrhosis + diabetes + bronze skin — represents end-organ damage and is less commonly the presenting picture today in countries with good access to laboratory screening. When all three are present simultaneously, iron loading has typically exceeded 20–40 g.

Other Late Manifestations

Vibrio vulnificus infection risk: Patients with hemochromatosis are at dramatically increased risk of fatal Vibrio vulnificus septicemia from eating raw shellfish (particularly oysters). Iron is a critical growth factor for this organism, and the iron-rich milieu of hemochromatosis patients enables explosive bacterial replication. Patients should be counseled to avoid raw shellfish entirely.

Diagnosis

Diagnosis integrates biochemical iron studies, genetic testing, and — when indicated — imaging or liver biopsy. The goal is to identify iron overload and confirm the genetic cause before irreversible organ damage occurs.

Step 1: Transferrin Saturation

Fasting transferrin saturation (TS) is the best initial screening test. It is calculated as (serum iron ÷ total iron-binding capacity) × 100. A value above 45% is the accepted screening threshold; values above 62% in men are highly suspicious for C282Y homozygosity. TS should be measured fasting and repeated on at least one occasion before proceeding, as transient elevation can occur with acute-phase reactions.

Step 2: Serum Ferritin

Serum ferritin reflects total body iron stores but is a non-specific marker — it rises with inflammation, infection, alcohol use, metabolic syndrome, and cancer. In a patient with elevated TS, a high ferritin (typically >200 ng/mL in women and >300 ng/mL in men) provides corroborating evidence. Ferritin above 1,000 ng/mL is a red flag: at this level, risk of cirrhosis increases substantially and liver biopsy is usually indicated to assess fibrosis.

Step 3: HFE Genotyping

Once biochemical iron overload is confirmed, HFE genotyping for C282Y and H63D is ordered. C282Y homozygosity in a patient with elevated TS and ferritin establishes the diagnosis of HFE hereditary hemochromatosis without needing biopsy in most cases (unless ferritin >1,000 ng/mL or liver enzyme elevation raises concern for advanced fibrosis). Genotyping is also used to screen first-degree relatives.

Liver Biopsy

Liver biopsy remains the gold standard for assessing fibrosis stage but is now reserved for patients where advanced fibrosis or cirrhosis is suspected (ferritin >1,000 ng/mL, elevated AST/ALT, platelet count below 200,000, or age over 40 with elevated ferritin). Histology shows Prussian blue-staining iron in a periportal hepatocyte-predominant pattern (grade 1–4 by Scheuer system), and Metavir or Ishak scoring for fibrosis.

MRI T2* Imaging

MRI with T2* or R2* sequences provides non-invasive quantification of hepatic iron concentration — iron causes signal loss proportional to its concentration. MRI is increasingly used to avoid biopsy, particularly in patients who cannot tolerate the procedure. It is also useful for monitoring cardiac iron in juvenile hemochromatosis or in patients where cardiac involvement is suspected.

Hepatic Iron Index

Historically calculated from biopsy specimens as hepatic iron concentration (μmol/g dry weight) divided by age. A hepatic iron index above 1.9 was a classic diagnostic threshold, but genotyping has largely replaced this calculation.

Treatment: Phlebotomy and Beyond

The treatment for hereditary hemochromatosis is elegant in its simplicity: remove blood. Phlebotomy is inexpensive, safe, and highly effective when started before organ damage is established. It is the standard of care endorsed by all major gastroenterology and hematology societies.

Therapeutic Phlebotomy

Induction phase: Weekly removal of 450–500 mL of whole blood (equivalent to a standard blood donation unit). Each unit removes approximately 200–250 mg of iron. With a total body excess of 10–30 g, patients typically require 40–80 weekly phlebotomies over 1–2 years before target ferritin is reached. Hemoglobin is checked before each session; phlebotomy is held if hemoglobin falls below 11 g/dL (to allow erythropoiesis to replenish red cells and draw stored iron into circulation).

Target: Serum ferritin below 50 ng/mL (some guidelines target 50–100 ng/mL). Once achieved, the induction phase ends.

Maintenance phase: After target ferritin is reached, most patients need phlebotomy every 3–4 months (2–4 units per year) to maintain iron balance. This is usually lifelong.

Blood donation: In many countries, blood donated by patients with hemochromatosis is accepted for transfusion — a win-win that improves blood supply access while providing free therapeutic phlebotomy. In the United States, the FDA permits this; check current local guidelines.

Iron Chelation

For patients who cannot tolerate phlebotomy — primarily those with severe anemia, heart failure, or poor venous access — deferasirox (oral, once daily) or deferoxamine (subcutaneous infusion, 8–12 hours/night, 5–7 nights per week) provide pharmacological iron removal. Chelation is less efficient than phlebotomy at removing total iron burden and is significantly more expensive. Deferoxamine is used more commonly in secondary iron overload (thalassemia, sideroblastic anemia) than in HFE hemochromatosis.

Dietary Guidance

Screening and Prevention

Family Screening

First-degree relatives (parents, siblings, children) of a confirmed C282Y homozygote should be offered HFE genotyping. If a sibling is C282Y homozygous, they have a 25% probability of the same genotype. Because hemochromatosis is autosomal recessive, both parents are obligate C282Y heterozygotes; children have a 25% chance of inheriting both mutant alleles only if the other parent is also a carrier (carrier frequency ~10% in Northern Europeans). Early identification enables treatment before organ damage occurs, potentially normalizing life expectancy entirely.

Population Screening Debates

Population-level HFE genotyping screening has been debated for decades. Arguments in favor: the disease is common, treatment is cheap and effective, and early detection is curative. Arguments against: incomplete penetrance (many C282Y homozygotes never develop clinical disease), psychological burden of a genetic diagnosis, and insurance discrimination concerns. Current AASLD guidelines do not recommend universal population screening but do recommend targeted screening in individuals with elevated transferrin saturation on routine blood work, and cascade family screening from known probands.

Opportunistic Biochemical Screening

Because transferrin saturation and ferritin are inexpensive and often included in metabolic panels, many patients are now identified incidentally. A fasting transferrin saturation above 45% on two separate occasions warrants HFE genotyping regardless of symptoms.

Prognosis and Complications

Excellent Prognosis with Early Treatment

Patients diagnosed and treated before the development of cirrhosis or diabetes have a normal life expectancy. The landmark study by Niederau et al. (1996) demonstrated this clearly: survival of hemochromatosis patients without cirrhosis and without diabetes was identical to matched controls. This is the central message — early detection and regular phlebotomy is curative in the most meaningful sense.

Hepatocellular Carcinoma

The most feared complication in patients who have already developed cirrhosis is HCC. The risk remains elevated at 20 times the background rate even after successful iron depletion in cirrhotic patients. For this reason, patients with established cirrhosis should undergo HCC surveillance with liver ultrasound every 6 months regardless of treatment response.

Which Complications Are Reversible?

Pregnancy Considerations

Pregnancy is generally safe for women with HH. The demands of fetal development actually assist in iron depletion during pregnancy, and the return of menstruation postpartum continues to provide some protection. Women with advanced liver disease require careful obstetric management. Genetic counseling is appropriate, particularly if the partner is a known HFE carrier.

Key Research Papers

PubMed searches for the latest hemochromatosis research:

References

  1. Feder JN, et al. A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13(4):399–408. PMID: 8696333. https://doi.org/10.1038/ng0896-399
  2. Bacon BR, et al. Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(1):328–343. PMID: 21452290. https://doi.org/10.1002/hep.24330
  3. Adams PC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352(17):1769–1778. PMID: 15858186. https://doi.org/10.1056/NEJMoa041534
  4. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010;139(2):393–408. PMID: 20542038. https://doi.org/10.1053/j.gastro.2010.06.013
  5. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434–1443. PMID: 22342938. https://doi.org/10.1016/j.bbamcr.2012.01.014
  6. Brissot P, et al. Haemochromatosis. Nat Rev Dis Primers. 2018;4:18016. PMID: 29620054. https://doi.org/10.1038/nrdp.2018.16
  7. Allen KJ, et al. Iron-overload–related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358(3):221–230. PMID: 18199861. https://doi.org/10.1056/NEJMoa073286
  8. Pilling LC, et al. Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank. BMJ. 2019;364:k5222. PMID: 30670482. https://doi.org/10.1136/bmj.k5222
  9. Niederau C, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110(4):1107–1119. PMID: 8613000. https://doi.org/10.1053/gast.1996.v110.pm8613000
  10. Valenti L, et al. Hereditary hemochromatosis and cancer risk: a systematic review and meta-analysis. Int J Cancer. 2012;131(1):1–11. PMID: 22020542. https://doi.org/10.1002/ijc.27318
  11. Fernandez-Real JM, et al. Iron stores, blood donation, and insulin sensitivity and secretion. Clin Chem. 2005;51(7):1201–1205. PMID: 15855291. https://doi.org/10.1373/clinchem.2004.046847
  12. van Bokhoven MA, et al. Complications of hereditary haemochromatosis. Eur J Gastroenterol Hepatol. 2003;15(9):993–999. PMID: 12923372. https://doi.org/10.1097/00042737-200309000-00004

Back to Table of Contents

Connections